prime iv semaglutide cost Quarterly Drug Pipeline: April 2025 - Therapeutics ✨ BIG NEWS ✨ We've

Fiber gummies will have the same effect, she says

In a call with investors after the results were announced, Martin Lange, executive vice president of R&D, chief scientific officer and member of the Management Board for Novo Nordisk, explained that Zepbound performed unusually well on efficacy compared to what has typically been reported in most previous trials of a similar nature. In a phase 3 trial in adults with pre-diabetes and obesity, participants had an average weight reduction of 22.9% on the highest dose of tirzepatide, 2.1% less weight loss than was seen in the CagriSema comparator trial

The Phase 2 trial did not report elevated rates of myocardial infarction in participants

Ulian MD, Unsain RF, Franco RR, Santo MA, Brewis A, Trainer S, et al